Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097279 · ClinicalTrials.gov registry record · Phase 3
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT00097279 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 230 participants.
The verdict
NCT00097279, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood glucose.
Interventions
- DRUG metformin
- DRUG biphasic insulin aspart
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097279
The ClinicalTrials.gov registry entry for NCT00097279 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which metformin is the first listed.
NCT00097279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097279 about?
NCT00097279 is a clinical study titled "Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes". This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood...
What is the current status of trial NCT00097279?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2004-08. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00097279?
The interventions under investigation include: metformin (DRUG), biphasic insulin aspart (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00097279?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.